Advertisement

Updated June 7th, 2020 at 18:42 IST

Fujifilm says COVID-19 drug research might get extended till July

Japanese company Fujifilm’s research on its anti-flu drug as a possible treatment for COVID-19 may stretch to July, a company spokesperson said on July 6.

Reported by: Riya Baibhawi
Fujifilm says COVID-19 drug research might get extended till July
| Image:self
Advertisement

Japanese company Fujifilm’s research on its anti-flu drug as a possible treatment for COVID-19 may stretch to July, a company spokesperson said on July 6. The subsidiary for the Fujifilm holdings started testing the anti-flu drug, Avigan after it yielded results on COVID-19 patients in China. According to the company, Avigan could shorten the total time required by coronavirus patients to recover.

In April, the company began clinically testing the drug with the testings was scheduled to end in June. However, a report in Japanese newspaper alleged that the final approval of the drug would be delayed until July due to lack of patient for testing. Commenting on the report, a Fujifilm spokesman reportedly said that there was a possibility that the clinical trials would continue in July.

Read: Experts Voice Concerns Over US Government's Program For COVID-19 Vaccine

Read: Maha Govt Allows Capture Of Rhesus Monkeys For Vaccine Research

Lack of patients?

According to reports, the firm was expected to give the approval for the drug in May but it was then postponed to June. However, a review by Japan's largest financial newspaper stated that the researchers were only able to get 70 per cent of the total patients required for the trial and since it took 28 days, the process would continue till July

The trial involved the drug to be administered for a maximum of 14 days to coronavirus patients between 20 and 74 years old with mild pneumonia. The study excludes pregnant women due to side effects shown in animal testing, he added. However, the delay has come as a major setback to the company racing to develop a vaccine for Coronavirus

On the other hand, Oxford University’s Jenner Institute, working with the Oxford Vaccine Group has developed a potential vaccine AZD1222, formerly known as ChAdOx1 nCoV-19. Oxford University recently announced the start of Phase II/III trial of AZD1222 in about 10,000 adult volunteers. The new vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold (adenovirus) virus that causes infections in chimpanzees and contains the genetic material of SARS-CoV-2 spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack COVID-19 if it later infects the body.

Read: AstraZeneca Aims To Boost Potential Supply Of COVID-19 Vaccine To 2 Billion

Read:  China Will Make Any Vaccine 'global Public Goods'
 

Advertisement

Published June 7th, 2020 at 18:42 IST

Your Voice. Now Direct.

Send us your views, we’ll publish them. This section is moderated.

Advertisement
Advertisement

Trending Quicks

Pooja Vastrekar
a few seconds ago
Congress Press Conference
12 minutes ago
Crew posters
17 minutes ago
Big Communication Gap Within the Congress: Sanjay Nirupam Targets Party Leadership | EXCLUSIVE
18 minutes ago
VST Tillers Tractors
19 minutes ago
High-net-worth women show a nuanced approach to wealth with interest in alternative investments and cautious risk tolerance.
19 minutes ago
Shreyas Iyer
25 minutes ago
France has approached 46 countries for the possible provision of over 2,000 police officers and several military personnel.
38 minutes ago
Advertisement
Advertisement
Advertisement
Whatsapp logo